

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

09 Jun 2026

### Study of efficacy and side effects of Pioglitazone in the treatment of plaque psoriasis vulgaris

#### Protocol summary

Research Council of Mashhad University of Medical Sciences

#### Summary

This study is a before-after clinical trial. The participants receive 30 mg/day of pioglitazone for 30 month (12 weeks) after evaluating inclusion and exclusion criteria and completing consent form. The PASI score and plaques specifications of patients are recorded monthly. In each visit the amount of scales, erythema and thickness of lesions and covering percentage are recorded into the checklists. Physical examinations and laboratory findings are entered in tables at each session.

#### Expected recruitment start date

2007-09-26, 1386/07/04

#### Expected recruitment end date

2010-11-25, 1389/09/04

#### Actual recruitment start date

empty

#### Actual recruitment end date

empty

#### Trial completion date

empty

#### General information

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT138903013862N2**

Registration date: **2010-06-08, 1389/03/18**

Registration timing: **registered\_while\_recruiting**

Last update:

Update count: **0**

##### Registration date

2010-06-08, 1389/03/18

##### Registrant information

###### Name

Farahzad Jababri Azad

###### Name of organization / entity

Mashhad University of Medical Sciences

###### Country

Iran (Islamic Republic of)

###### Phone

+98 51 1843 6626

###### Email address

banihashemim@mums.ac.ir

##### Recruitment status

**Recruitment complete**

##### Funding source

#### Scientific title

Study of efficacy and side effects of Pioglitazone in the treatment of plaque psoriasis vulgaris

#### Public title

Study of efficacy and side effects of Pioglitazone in the treatment of psoriasis

#### Purpose

Treatment

#### Inclusion/Exclusion criteria

Inclusion criteria: new cases of plaque psoriasis which don't received systematic treatment during last 3 months and for topical treatment last month, patients complete consent form and participate to study consciously. Exclusion criteria: patients who want to leave study deliberately, sensitive to pioglitazone or the same preparations, type one diabetes mellitus, pregnant or lactating women, below 18 years old, with severe hepatic problems (hepatitis, alcoholic or non alcoholic steatohepatitis, cirrhosis), severe cardiovascular disorders (NYHA CLASS III & IV), patients prevent pregnancy only by oral contraceptives, patients that have any of these following side effects during therapy: upper respiratory tract infections and sinusitis, edema and any indicative sign of heart failure, unwanted pregnancy, weight gain, anemia, leucopenia, hematuria, jaundice and 3 times increment of hepatic enzymes

(ALT), any symptom which make patients to leave the study. Patients who used any of these drugs (Oral contraceptives, Gatifloxacin ,Insulin ,sulfunamides ,sulfunylureas, Thioridazine , Gemfibrozil).

#### Age

From **18 years** old to **80 years** old

#### Gender

Both

#### Phase

2-3

#### Groups that have been masked

*No information*

#### Sample size

Target sample size: **26**

#### Randomization (investigator's opinion)

N/A

#### Randomization description

#### Blinding (investigator's opinion)

Not blinded

#### Blinding description

#### Placebo

Not used

#### Assignment

Single

#### Other design features

## Secondary Ids

empty

## Ethics committees

### 1

#### Ethics committee

##### Name of ethics committee

Ethics Committee of Mashad University of Medical Sciences

##### Street address

Central Building of Mashad University of Medical Sciences, Mashad, Iran

##### City

Mashhad

##### Postal code

#### Approval date

2007-10-26, 1386/08/04

#### Ethics committee reference number

286255

## Health conditions studied

### 1

#### Description of health condition studied

Psoriasis

#### ICD-10 code

L40.0

#### ICD-10 code description

Psoriasis vulgaris

## Primary outcomes

### 1

#### Description

Psoriasis severity

#### Timepoint

monthly untill the end of 12 weeks

#### Method of measurement

PASI standard method

## Secondary outcomes

### 1

#### Description

side effect

#### Timepoint

monthly untill end of 12 weeks

#### Method of measurement

Standard evaluation method for this disease

## Intervention groups

### 1

#### Description

oral Pioglitazone 30 mg daily for 12 weeks

#### Category

Treatment - Drugs

## Recruitment centers

### 1

#### Recruitment center

##### Name of recruitment center

Research center of skin disease and cutaneous leishmaniasis, Ghaem Hospital

##### Full name of responsible person

Dr Pouran Layegh, Dr sayed Rahman Movahed Ghodsinia

##### Street address

Ghaem Hospital, Ahmad Abad Street

##### City

Mashhad

## Sponsors / Funding sources

### 1

#### Sponsor

##### Name of organization / entity

Research Council of Mashhad University of Medical Sciences

##### Full name of responsible person

Vice chancellor for research of Mashhad University of Medical Sciences

##### Street address

Central Building of Mashhad University of Medical Sciences

**City**  
Mashhad

**Grant name**

**Grant code / Reference number**

**Is the source of funding the same sponsor organization/entity?**  
Yes

**Title of funding source**  
Research Council of Mashhad University of Medical Sciences

**Proportion provided by this source**  
100

**Public or private sector**  
*empty*

**Domestic or foreign origin**  
*empty*

**Category of foreign source of funding**  
*empty*

**Country of origin**

**Type of organization providing the funding**  
*empty*

## Person responsible for general inquiries

### Contact

**Name of organization / entity**  
Research center for skin disease and cutaneous leishmaniasis

**Full name of responsible person**  
Hadis Yousefzadeh

**Position**  
Master of Sciences, Biologist

**Other areas of specialty/work**

**Street address**  
Research center of skin diseases and leishmaniasis, Office building, Ghaem Hospital, Ahmad Abad Street

**City**  
Mashhad

**Postal code**

**Phone**  
+98 51 1732 7027

**Fax**

**Email**  
hadis\_yousefzadeh@yao.com

**Web page address**

## Person responsible for scientific inquiries

### Contact

**Name of organization / entity**  
Mashad University of Medical Sciences

**Full name of responsible person**  
Dr Poursan Layegh

**Position**

Associate Professor of Dermatology

**Other areas of specialty/work**

**Street address**  
Department of Dermatology, Qaem Hospital, Mashhad University of Medical Sciences

**City**  
Mashhad

**Postal code**

**Phone**  
+98 51 1881 4988

**Fax**

**Email**  
layeghpo@mums.ac.ir

**Web page address**

## Person responsible for updating data

### Contact

**Name of organization / entity**  
Research center for skin disease and cutaneous leishmaniasis

**Full name of responsible person**  
Hadis Yousefzadeh

**Position**  
Master of Sciences, Biologist

**Other areas of specialty/work**

**Street address**  
Research center of skin diseases and leishmaniasis, Office building, Ghaem Hospital, Ahmad Abad Street

**City**  
Mashhad

**Postal code**

**Phone**  
+98 51 1841 0135

**Fax**

**Email**  
hadis\_yousefzadeh@yahoo.com

**Web page address**

## Sharing plan

### Deidentified Individual Participant Data Set (IPD)

*empty*

### Study Protocol

*empty*

### Statistical Analysis Plan

*empty*

### Informed Consent Form

*empty*

### Clinical Study Report

*empty*

### Analytic Code

*empty*

### Data Dictionary

*empty*